For an adult with type 2 diabetes and a known heart condition, are sodium‑glucose cotransporter‑2 (SGLT2) inhibitors or glucagon‑like peptide‑1 (GLP‑1) receptor agonists the preferred therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

SGLT-2 Inhibitors and GLP-1 Receptor Agonists Are Both Strongly Recommended—Choice Depends on Heart Failure Status

For a diabetic with a heart condition, if heart failure is present or suspected, use an SGLT-2 inhibitor first; if the heart condition is primarily atherosclerotic disease (prior MI, stroke, or coronary disease) without heart failure, either class is appropriate, though GLP-1 receptor agonists may have a slight edge for preventing recurrent atherosclerotic events. Both classes reduce mortality and major cardiovascular events with high certainty evidence 1, 2.

The Core Recommendation Framework

The 2025 BMJ living guideline provides the clearest directive: for adults with type 2 diabetes at higher risk of cardiovascular complications (defined as established CVD or CKD), both SGLT-2 inhibitors and GLP-1 receptor agonists receive a strong recommendation in favor 1. This is based on 110 trials with 86,803 participants for SGLT-2 inhibitors and 109 trials with 102,687 participants for GLP-1 receptor agonists, demonstrating high certainty evidence for survival benefits and moderate-to-high certainty for cardiovascular and kidney outcomes 1.

The 2025 American Diabetes Association Standards of Care echo this, stating that among people with type 2 diabetes who have established atherosclerotic cardiovascular disease (ASCVD) or established kidney disease, either an SGLT-2 inhibitor or GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended 2.

How to Choose Between Them

If Heart Failure Is Present or Dominant:

Choose SGLT-2 inhibitors. The guideline explicitly states that "adults with established heart failure may favour SGLT-2 inhibitors over alternatives" 1. SGLT-2 inhibitors reduce hospitalization for heart failure by approximately 32% (HR 0.68) 3, a benefit substantially greater than GLP-1 receptor agonists 4. The ADA guidelines specifically recommend SGLT-2 inhibitors with demonstrated cardiovascular benefit to reduce the risk of heart failure hospitalization 2. This heart failure benefit is so robust that SGLT-2 inhibitors are recommended for heart failure patients irrespective of diabetes status 1.

If Atherosclerotic Disease Is Dominant (Prior MI, Stroke, Coronary Disease):

Either class is appropriate, with GLP-1 receptor agonists having a numerical advantage for atherosclerotic events. A 2026 network meta-analysis of patients with type 2 diabetes and prior myocardial infarction found both classes significantly reduced major adverse cardiovascular events (MACE) compared to placebo, with no statistically significant difference between them (indirect HR 1.05,95% CI 0.92-1.20, p=0.44) 5. However, a 2025 meta-analysis found GLP-1 receptor agonists showed nominally greater MACE reduction (indirect HR 1.09,95% CI 1.00-1.18, p=0.0497) 3, and a 2021 network meta-analysis demonstrated that GLP-1 receptor agonists reduced non-fatal stroke more than SGLT-2 inhibitors, which appeared to have no effect on stroke 4.

If Chronic Kidney Disease Is Present:

SGLT-2 inhibitors have superior renal protection. They reduce composite renal outcomes by 31% (HR 0.69) 3, a more pronounced benefit than GLP-1 receptor agonists 3. The ADA recommends SGLT-2 inhibitors specifically for patients with established kidney disease 2.

If Atrial Fibrillation Coexists:

GLP-1 receptor agonists may be preferred. A 2026 comparative effectiveness study found GLP-1 receptor agonists associated with lower AF progression (HR 0.94), AF ablation (HR 0.81), and cardioversion (HR 0.79) compared to SGLT-2 inhibitors 6.

Combination Therapy Is an Option

Both drugs can be combined for potentially additive benefits 1, 2. The BMJ guideline states that SGLT-2 inhibitors and GLP-1 receptor agonists can be combined, and the ADA notes that combined therapy "may be considered for additive reduction of the risk of adverse cardiovascular and kidney events" 2. A 2026 meta-analysis suggests possible additive benefits, though most evidence is indirect 7, 8.

Practical Considerations

Side Effect Profiles:

  • SGLT-2 inhibitors: Cause genital infections (high certainty) 4. Avoid if risk of diabetic ketoacidosis exists 9. Most effective if eGFR >60 mL/min/1.73m² at initiation 9.
  • GLP-1 receptor agonists: May cause severe gastrointestinal events (low certainty) 4. Contraindicated with history of medullary thyroid cancer; use with caution if history of pancreatitis 9.

Persistence Data:

Real-world evidence shows SGLT-2 inhibitors have higher 1-year persistence (47.0%) compared to GLP-1 receptor agonists (37.6%) 10, possibly reflecting better tolerance, oral formulation preference, and fewer side effects.

The Bottom Line Algorithm

  1. Does the patient have heart failure? → SGLT-2 inhibitor
  2. Does the patient have significant CKD (eGFR <60)? → SGLT-2 inhibitor
  3. Is the heart condition primarily atherosclerotic (prior MI/stroke) without heart failure? → Either class; slight preference for GLP-1 receptor agonist for stroke prevention
  4. Does the patient have atrial fibrillation? → Consider GLP-1 receptor agonist
  5. Does the patient need substantial weight loss? → GLP-1 receptor agonist has greater weight reduction 3
  6. For maximal cardiovascular and renal protection in very high-risk patients → Consider combination therapy 1, 2

References

Related Questions

For adults with type 2 diabetes, which is more effective at lowering blood glucose: glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) or sodium‑glucose co‑transporter‑2 inhibitors (SGLT‑2 inhibitors)?
Compare the described type 2 diabetes management approach—metformin first, early addition of a sodium‑glucose co‑transporter‑2 inhibitor (SGLT2 inhibitor) or glucagon‑like peptide‑1 receptor agonist (GLP‑1 RA) for cardiovascular disease, heart failure, chronic kidney disease, or weight loss, and basal insulin only after non‑insulin agents fail—to the NICE United Kingdom guidelines, and present the comparison in a table.
Is a sodium‑glucose co‑transporter‑2 (SGLT2) inhibitor an appropriate alternative to a glucagon‑like peptide‑1 (GLP‑1) receptor agonist for managing type 2 diabetes in a patient who cannot tolerate GLP‑1 therapy?
What are the third and fourth line agents to add for the treatment of type 2 diabetes mellitus (Type 2 DM)?
Are any GLP-1 (Glucagon-like peptide-1) or GLP-2 (Glucagon-like peptide-2) agonists not contraindicated in patients with a first-degree relative with thyroid cancer?
What do anti‑Ro (SSA), anti‑La (SSB), and anti‑Sa antibodies test for?
Should the prednisone dose be adjusted for a patient on dialysis receiving 50 mg daily for an acute COPD exacerbation?
What are the maximum recommended daily doses for all psychiatric medications?
Is the patient's elevated total and free testosterone contributing to her diffuse hair loss?
Is witch hazel an appropriate treatment for hemorrhoids?
What medications, including dose and frequency, are appropriate for a 75‑year‑old patient with depression, panic attacks, anxiety, and a desire to quit smoking?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.